This capability may be related to memory CD8+ T cells after treatment interruption, which have a stronger antiviral potential if treatment is initiated within four weeks of infection (as was the case for most participants in the VISCONTI study), suggesting a window of opportunity to achieve HIV infection remission [32]. Here, CD8A is linked to HIV infectious disease.